Skip to content

TADAFL

Safety trial of tadalafil administered during labor A phase-1 clinical study - TADAFL

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs041210073
Enrollment
12
Registered
2021-09-22
Start date
2021-10-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy Singlton

Interventions

Cohort I: Start taking tadalafil 10 mg (Zartia Coupling Tablets 5 mg, 2 tablets) from the beginning of labor, and take the same amount every 12 hours. Cohort II: Start oral administration of tadalafil

Sponsors

Tanaka Hiroaki
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 20 years old and under 45 years old It is predicted that the baby will be delivered after 37 weeks of gestation and less than 42 weeks. 28 weeks or more and less than 41 weeks gestation The expected delivery date has been determined in accordance with the Obstetrics and Gynecology Practice Guidelines Obstetrics Edition 2020. Single fetal flow. A written consent has been obtained from the person mother regardingregarding participation in the test.

Exclusion criteria

Exclusion criteria: Pregnant women whose delivery method is defined as cesarean section before the start of labor (previous cesarean section, post myomectomy. Has a history of hypersensitivity to tadalafil. Patients who used PDE5 inhibitors containing tadalafil during this pregnancy. I am taking a drug that is contraindicated in combination with the drug in the package insert of tadalafil. Patients undergoing renal dialysis or having severe renal dysfunction with measured or estimated creatinine clearance of less than 30 mL / min. Patients with severe hepatic disorder [patients with AST (GOT) or ALT (GPT) of 100 IU / L or more]. Patients with uncontrolled arrhythmia, hypotension (blood pressure 170/100 mmHg). When fetal morphological abnormalities including multiple malformations that may be chromosomal abnormalities are observed in the foetation by fetal ultrasonography. Patients with retinitis pigmentosa, hemorrhagic disease, peptic ulcer, or pulmonary vein obstructive disease. Patients who are judged by the principal investigator or the investigator to be unsuitable for the study.

Design outcomes

Primary

MeasureTime frame
Maternal Safty

Secondary

MeasureTime frame
Pharmacokinetic parameters: AUC0 12, Cmax Comparison of placental PlGF and prepartum PlGF in cesarean section and transvaginal delivery by fetal adaptation, adverse events in newborns

Contacts

Public ContactHiroaki Tanaka

Mie University Hospital

tanaka-hiroaki@med.mie-u.ac.jp+81-592321111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026